Kolexia
Ferrero Jean Marc Oncologie médicale
Ferrero Jean Marc
Oncologie médicale
Centre Antoine Lacassagne
Nice, France
374 Activités
61 Followers
Scientifique
Digital
Production scientifique
Activités par an
Expertise
Sujets de recherche
{{person.topmesh1.name}} Tumeurs du sein Métastase tumorale Tumeurs de la prostate Tumeurs du sein triple-négatives Récidive tumorale locale Tumeur du sein de l'homme Carcinomes Cancers du sein inflammatoires Métastase lymphatique

Collaborateurs

Voir plus
Bachelot Thomas
Bachelot Thomas
Centre Léon-Bérard, Lyon, France
Levy Christelle
Levy Christelle
Centre François-Baclesse, Caen, France
Petit Thierry
Petit Thierry
Centre Paul Strauss, Strasbourg, France
Goncalves Anthony
Goncalves Anthony
Centre Paoli-Calmettes, Marseille, France

Industries

Voir plus
Novartis
18 collaboration(s)
Dernière en 2023
Pfizer
18 collaboration(s)
Dernière en 2023
Lilly
11 collaboration(s)
Dernière en 2023
AstraZeneca
10 collaboration(s)
Dernière en 2023

Dernières activités

Voir plus
HER2CLIMB-05: A Randomized, Double-blind, Phase 3 Study of Tucatinib or Placebo in Combination With Trastuzumab and Pertuzumab as Maintenance Therapy for Metastatic HER2+ Breast Cancer (HER2CLIMB-05)
Essai Clinique (Seagen)   15 mars 2024
POLAR: A Phase III Open-label, Multicenter, Randomized Trial of Adjuvant Palbociclib in Combination With Endocrine Therapy Versus Endocrine Therapy Alone for Patients With Hormone Receptor Positive / HER2-negative Resected Isolated Locoregional Recurrence of Breast Cancer
Essai Clinique (Pfizer)   05 mars 2024
Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer: A Phase III, Randomized Clinical Trial of Standard Adjuvant Endocrine Therapy +/- Chemotherapy in Patients With 1-3 Positive Nodes, Hormone Receptor-Positive and HER2-Negative Breast Cancer With Recurrence Score (RS) of 25 or Less. RxPONDER: A Clinical Trial Rx for Positive Node, Endocrine Responsive Breast Cancer
Essai Clinique (National Cancer Institute)   14 février 2024
Author Correction: Paclitaxel plus carboplatin and durvalumab with or without oleclumab for women with previously untreated locally advanced or metastatic triple-negative breast cancer: the randomized SYNERGY phase I/II trial.
Nature communications   12 décembre 2023
Overall Survival With Circulating Tumor Cell Count-Driven Choice of Therapy in Advanced Breast Cancer: A Randomized Trial.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology   06 novembre 2023
Paclitaxel plus carboplatin and durvalumab with or without oleclumab for women with previously untreated locally advanced or metastatic triple-negative breast cancer: the randomized SYNERGY phase I/II trial.
Nature communications   02 novembre 2023
Chemotherapy-Related Amenorrhea and Quality of Life Among Premenopausal Women With Breast Cancer.
JAMA network open   01 novembre 2023
Long term activity of vemurafenib in cancers with BRAF mutations: the ACSE basket study for advanced cancers other than BRAF -mutated melanoma.
ESMO open   01 novembre 2023
Survival analysis of patient groups defined by unsupervised machine learning clustering methods based on patient metabolomic data.
Computational and structural biotechnology journal   19 octobre 2023
362P CYBERNEO trial: Update of results at 14 years of follow-up
Abstract Book of the ESMO Congress 2023, 20 - 24 October 2023.   01 octobre 2023